Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Université de Lille | OTHER |
| Région Nord-Pas de Calais, France | OTHER |
| La Ligue Française Contre la Sclérose en Plaques | OTHER |
| Novartis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to measure economic burden of Multiple Sclerosis (MS) from a new point of view that includes consequences of disability on Quality Of Life (QOL), social participation and capabilities of patients and caregivers. To the investigators' knowledge, there is currently no data including intangible costs related to caregivers and calculating the overall economic cost of Multiple Sclerosis, particularly, in France.
The goal of this study is to evaluate prospectively the economic burden of Multiple Sclerosis (MS) in France by calculating direct costs (medical and non-medical) and indirect costs and by estimating consequences of MS on utility (QALY) of patients and caregivers in a societal perspective.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Annual average total health care cost of the Multiple Sclerosis by patient | Global cost of Multiple Sclerosis considering direct medical and non-medical costs as well as the indirect and intangible costs associated to the patient-caregiver | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Score of social participation | Correlation between the score of social participation and health care costs of the disease will be determined | 1 year |
| Validity of life quality measurement EQ-5D |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
At least 230 patients in secondary and tertiary centers (8) affiliated to the regional supportive care network (GSEP) in north of France.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arnaud KWIATKOWSKI | Groupement des Hôpitaux de l'Institut Catholique de Lille | Principal Investigator |
| Amélie LANSIAUX | Groupement des Hôpitaux de l'Institut Catholique de LilleGroupement des Hôpitaux de l'Institut Catholique de Lille | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D000086522 | Financial Stress |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| INDUSTRY |
Not provided
Not provided
Not provided
The EQ-5D index is a generic measure of health status that provides a simple descriptive profile and a single index value that can be used in the clinical and economic evaluation of health care
| 1 year |
| Utilities measured by the Short Form-6D (SF-6D) | The SF-6D is a utility index based on a descriptive system composed of 11 items from six dimensions of the SF-36: physical functioning, role limitations, social functioning, pain, mental functioning and vitality. | 1 year |
| QALY | Health related quality in life will be measured as Quality adjusted life years (QALY) | 1 year |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D013315 | Stress, Psychological |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |